Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model

doi:10.3390/ijms21041433

CNU IR > Pharmacy and Science > Dept. of Health and Nutrition (including master's program) > Periodical Articles > Item 310902800/34143

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34143

Title:	Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model
Authors:	Chen, Shih-Han Sun, Jui-Ming Chen, Bing-Mao Lin, Sheng-Che Chang, Hao-Fang Collins, Sara Chang, Deching Wu, Shu-Fen Lu, Yin-Che Wang, Weijun Chen, Thomas C. Kasahara, Noriyuki Wang, Hsin-Ell Tai, Chien-Kuo
Contributors:	Ditmanson Med Fdn, Dept Surg, Sect Neurosurg, Chia Yi Christian Hosp Asia Univ, Dept Biotechnol Natl Chung Cheng Univ, Dept Biomed Sci Univ Calif San Francisco, Dept Neurol Surg, San Francisco Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Univ Southern Calif, Dept Neurosurg, Los Angeles Univ Calif San Francisco, Dept Radiat Oncol, San Francisco Natl Yang Ming Univ, Dept Biomed Imaging & Radiol Sci
Keywords:	brain tumor retroviral replicating vector prodrug activator gene therapy E. coli nitroreductase gene
Date:	2020
Issue Date:	2022-11-18 11:25:48 (UTC+8)
Publisher:	Mdpi
Abstract:	Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma cells both in culture and in vivo. To avoid receptor interference and enable dual vector co-infection with MLV-RRV, we have developed another RRV based on gibbon ape leukemia virus (GALV) that also shows robust replicative spread in a wide variety of tumor cells. We evaluated the potential of GALV-based RRV as a cancer therapeutic agent by incorporating yeast cytosine deaminase (CD) and E. coli nitroreductase (NTR) prodrug activator genes into the vector. The expression of CD and NTR genes from GALV-RRV achieved highly efficient delivery of these prodrug activator genes to RG-2 glioma cells, resulting in enhanced cytotoxicity after administering their respective prodrugs 5-fluorocytosine and CB1954 in vitro. In an immune-competent intracerebral RG-2 glioma model, GALV-mediated CD and NTR gene therapy both significantly suppressed tumor growth with CB1954 administration after a single injection of vector supernatant. However, NTR showed greater potency than CD, with control animals receiving GALV-NTR vector alone (i.e., without CB1954 prodrug) showing extensive tumor growth with a median survival time of 17.5 days, while animals receiving GALV-NTR and CB1954 showed significantly prolonged survival with a median survival time of 30 days. In conclusion, GALV-RRV enabled high-efficiency gene transfer and persistent expression of NTR, resulting in efficient cell killing, suppression of tumor growth, and prolonged survival upon CB1954 administration. This validates the use of therapeutic strategies employing this prodrug activator gene to arm GALV-RRV, and opens the door to the possibility of future combination gene therapy with CD-armed MLV-RRV, as the latter vector is currently being evaluated in clinical trials.
Relation:	International Journal of Molecular Sciences, v.21, n.4, pp.12
Appears in Collections:	[Dept. of Health and Nutrition (including master's program)] Periodical Articles

Files in This Item:

File	Description	Size	Format
10.1016j.seppur.2020.117460.pdf		649Kb	Adobe PDF	132	View/Open
index.html		0Kb	HTML	505	View/Open

Loading...